Safety and Efficacy of BAF312 in Dermatomyositis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. The study was composed of 2 periods: a double-blind period 1 with BAF312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose Period 2 in which BAF312 was administered at the dose of 2 mg daily .
Epistemonikos ID: 4f181adf0dae9aa1b3651b028b9c945c4fea4482
First added on: May 11, 2024